Prosecution Insights
Last updated: November 04, 2026
Application No. 18/703,379

FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF

Non-Final OA §102§112
Filed
Apr 22, 2024
Priority
Aug 12, 2021 — IN 202141036582 +1 more
Examiner
ROZOF, TIMOTHY R
Art Unit
Tech Center
Assignee
Fathima Benazir
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
711 granted / 977 resolved
+12.8% vs TC avg
Strong +23% interview lift
Without
With
+23.1%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
54 currently pending
Career history
1027
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
21.3%
-18.7% vs TC avg
§102
32.9%
-7.1% vs TC avg
§112
25.6%
-14.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 977 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on August 24, 2026. Application No. 18/703,379, filed April 22, 2024, is a 371 of PCT/IN2022/050731, filed August 12, 2022, and claims foreign priority to Indian application No. INDIA 202141036582, filed August 12, 2021. In a preliminary amendment filed April 22, 2024, Applicant cancelled claims 3-19, 26, 27, and 31. Claims 1, 2, 20-25, 28-30, and 32-40 are pending. Election/Restrictions Applicant’s elections of the invention of Group I and the species of Compound J, in the reply filed on August 24, 2026, are acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 33-39 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claim 20 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species. The elections were made without traverse in the reply filed on August 24, 2026. The elected species is allowable. The search has been expanded accordingly. Claims 1, 2, 21-25, 28-30, 32 and 40 are examined below. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 2 and 40 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claims 2 is drawn to compounds of Formula (I), where A is not a polycyclic heterocyclic ring. For example wherein the elected species ring A forms a six membered aryl ring; not a heterocyclic ring. There is insufficient antecedent basis for this limitation in the claim. Claim 40 is drawn to the compounds of formula (I) as in claim 1 comprising molecules according to claims 4-19. Claims 4-19 have been cancelled. In addition, this claim is generally vague and unconventional in the art. It is unclear what molecules the claim is referring to. Appropriate correction is required. Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 21-25, 28-30, 32, and 40 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by Hong et al., 9(6) Antiviral Chem. & Chemotherapy, 461-472 (1998). Hong discloses the following compound: PNG media_image1.png 267 417 media_image1.png Greyscale (Hong et al., citing the CAS abstract for the compound depicted above.) This compound reads on a compound of Formula (I), where in Formula (I) ring is A is a hydroxy substituted aryl ring; R2 and R3 form an acyl, the above compound is a tautomer of that acyl moiety; the bound between rings B and C is saturated; X is O; and D(s) are CR4; one of R1/R4 is a hydroxy, the other is hydrogen. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached on Monday - Friday, 9:00 a.m. -5:00 p.m.. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached on (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Apr 22, 2024
Application Filed
Oct 08, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780853
INDOLE-CONTAINING MACROCYCLIC COMPOUNDS AND USES THEREOF
2y 2m to grant Granted Nov 03, 2026
Patent 12759980
COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS
4y 2m to grant Granted Oct 13, 2026
Patent 12751935
METHOD OF TREATING, AMELIORATING AND/OR PREVENTING DEPRESSION
3y 5m to grant Granted Oct 06, 2026
Patent 12751954
Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds
2y 11m to grant Granted Oct 06, 2026
Patent 12746234
USE OF COMPOSITION CONTAINING CILOSTAZOL IN CEREBROVASCULAR DISEASES
3y 2m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
96%
With Interview (+23.1%)
2y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 977 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month